Eyewire News

Featured Story

05.05.2026

Viridian Therapeutics Reports Positive Phase 3 Results for Thyroid Eye Disease Drug

Key Takeaways Elegrobart significantly improved key symptoms of chronic thyroid eye disease in a phase 3 trial, with responder rates exceeding placebo The treatment was generally well tolerated and offers a more convenient at-home injection option compared to existing therapies. Viridian plans to seek FDA approval in early 2027 Viridian Therapeutics announced positive topline data from the REVEAL‑2 phase 3 clinical trial of elegrobart in patients with chronic thyroid eye disease (TED).

Read Story

Latest News Stories

Ametek Reichert Expands Tele-Optometry Capabilities with SightChek Integration into DigitalOptometrics Platform image

05.05.2026

Ametek Reichert Expands Tele-Optometry Capabilities with SightChek Integration into DigitalOptometrics Platform

05.05.2026

Oculis Highlights New Global Consensus on Diabetic Macular Edema Care at ARVO

05.04.2026

IDOC Launches Clerra Lens Line to Simplify Dispensing and Reduce Costs for Independent Optometrists

Johnson & Johnson Showcases New Vision Research at ARVO 2026 image

05.04.2026

Johnson & Johnson Showcases New Vision Research at ARVO 2026

05.04.2026

Lineage Cell Therapeutics Reports 36-Month Data for OpRegen in Geographic Atrophy

05.04.2026

Myopia Profile Launches Consumer-Focused Myopia Control Product Compendium

05.04.2026

Atsena Therapeutics Reports Positive 6-Month Data from LIGHTHOUSE Trial of ATSN-201 in XLRS

CooperVision Launches MyDay Energys 180-Pack image

05.04.2026

CooperVision Launches MyDay Energys 180-Pack

05.01.2026

Sydnexis to Present New Subgroup Data from Phase 3 STAR Trial of SYD-101 at ARVO 2026

05.01.2026

Early Screening and Outdoor Activity Key to Tackling Childhood Myopia, Italian Study Finds

International Congress of Scleral Contacts: A Chance to Advance Your Skills image

05.01.2026

International Congress of Scleral Contacts: A Chance to Advance Your Skills

05.01.2026

Sun Pharma to Acquire Organon in $11.75 Billion All-Cash Deal

05.01.2026

Astellas Showcases New Geographic Atrophy Research at ARVO 2026

05.01.2026

EyePoint Outlines Poster Presentations at the ARVO 2026

Oculis Showcases Pipeline Innovations Ahead of Key Data Readouts at ARVO 2026 image

05.01.2026

Oculis Showcases Pipeline Innovations Ahead of Key Data Readouts at ARVO 2026

04.30.2026

Study Links Diabetic Retinopathy Severity to Higher Mortality Risk

04.30.2026

Genentech to Highlight Real-World and Pipeline Advances in Ophthalmology at ARVO 2026

Bausch + Lomb to Showcase Research Portfolio at ARVO 2026 image

04.30.2026

Bausch + Lomb to Showcase Research Portfolio at ARVO 2026

04.30.2026

NAMSA and Lexitas Forge Strategic Partnership to Advance Ophthalmic Device Development

View More

EyewireTV

Eyewire TV April 29, 2026 thumbnail

04.29.2026

The Latest EyewireTV

Brent Saunders, Bausch + Lomb

Julie Brewer, Alcon

Mark Baum, Harrow

Watch Episode

Watch the Latest Episode

Stay Updated

Sign up for Eyewire News and EyewireTV e‑newsletters to stay up to date on news in eye care!

Subscribe